J. Stern & Co. LLP Buys 10,806 Shares of Zoetis Inc. (NYSE:ZTS)

J. Stern & Co. LLP boosted its stake in Zoetis Inc. (NYSE:ZTS) by 5.7% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 199,953 shares of the company’s stock after purchasing an additional 10,806 shares during the quarter. Zoetis comprises about 4.2% of J. Stern & Co. LLP’s investment portfolio, making the stock its 13th largest holding. J. Stern & Co. LLP’s holdings in Zoetis were worth $39,067,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently added to or reduced their stakes in the stock. Asset Dedication LLC raised its position in shares of Zoetis by 4.8% in the 2nd quarter. Asset Dedication LLC now owns 1,174 shares of the company’s stock valued at $204,000 after acquiring an additional 54 shares during the period. Forza Wealth Management LLC increased its stake in Zoetis by 1.8% in the second quarter. Forza Wealth Management LLC now owns 3,313 shares of the company’s stock valued at $574,000 after purchasing an additional 58 shares in the last quarter. Cherry Creek Investment Advisors Inc. raised its holdings in Zoetis by 2.0% in the third quarter. Cherry Creek Investment Advisors Inc. now owns 3,021 shares of the company’s stock worth $590,000 after purchasing an additional 58 shares during the period. L. Roy Papp & Associates LLP boosted its position in shares of Zoetis by 2.8% during the second quarter. L. Roy Papp & Associates LLP now owns 2,221 shares of the company’s stock worth $385,000 after purchasing an additional 60 shares in the last quarter. Finally, Grove Bank & Trust grew its holdings in shares of Zoetis by 0.5% in the 3rd quarter. Grove Bank & Trust now owns 11,763 shares of the company’s stock valued at $2,298,000 after buying an additional 61 shares during the period. Institutional investors and hedge funds own 92.80% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages recently commented on ZTS. JPMorgan Chase & Co. raised their price objective on Zoetis from $225.00 to $230.00 and gave the stock an “overweight” rating in a research note on Friday, October 11th. Piper Sandler raised their price target on Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 14th. BTIG Research lifted their price objective on Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a report on Monday, August 12th. Argus raised Zoetis to a “strong-buy” rating in a research note on Friday, August 9th. Finally, Stifel Nicolaus raised their target price on shares of Zoetis from $200.00 to $210.00 and gave the stock a “buy” rating in a report on Wednesday, September 18th. Ten equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, Zoetis has a consensus rating of “Buy” and a consensus target price of $221.44.

Zoetis Stock Down 0.9 %

Shares of NYSE ZTS traded down $1.58 during midday trading on Tuesday, reaching $177.13. The company’s stock had a trading volume of 85,162 shares, compared to its average volume of 2,540,074. The stock has a 50 day simple moving average of $185.31 and a 200-day simple moving average of $180.79. The company has a current ratio of 3.69, a quick ratio of 2.27 and a debt-to-equity ratio of 1.26. The stock has a market capitalization of $79.92 billion, a price-to-earnings ratio of 33.59, a PEG ratio of 2.71 and a beta of 0.90. Zoetis Inc. has a fifty-two week low of $144.80 and a fifty-two week high of $201.92.

Zoetis (NYSE:ZTS) last released its earnings results on Monday, November 4th. The company reported $1.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.46 by $0.12. Zoetis had a return on equity of 51.98% and a net margin of 26.55%. The business had revenue of $2.40 billion for the quarter, compared to the consensus estimate of $2.29 billion. During the same quarter in the previous year, the business earned $1.36 earnings per share. Zoetis’s quarterly revenue was up 11.6% on a year-over-year basis. Equities research analysts predict that Zoetis Inc. will post 5.9 earnings per share for the current year.

Zoetis Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 3rd. Stockholders of record on Thursday, October 31st will be issued a $0.432 dividend. This represents a $1.73 annualized dividend and a dividend yield of 0.98%. The ex-dividend date of this dividend is Thursday, October 31st. Zoetis’s payout ratio is presently 32.52%.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.